{"presentation":{"slides":[{"elements":[{"x":5.446623093681917,"y":6.431440860215052,"width":89.32461873638344,"height":40.86021505376344,"action":{"library":"H5P.Table 1.1","params":{"text":"\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

Indicator <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t

Formula <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t

<\/td>\n\t\t<\/tr>\n\t\t

Proportion of notified persons with TB with UDST tested<\/span><\/strong> <\/td>\n\t\t\t

Numerator:<\/span><\/span><\/span><\/td>\n\t\t\t

Number of notified persons with TB<\/span><\/span><\/span> with<\/span><\/span><\/span> UDST tested.<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t\t

Denominator:<\/span><\/span><\/span> <\/td>\n\t\t\t

Total notified persons with TB<\/span><\/span><\/span> <\/td>\n\t\t<\/tr>\n\t\t

Multiplier:<\/span><\/span><\/span><\/td>\n\t\t\t

100<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"219f2587-5dbf-46da-bb22-0e75d00dda90","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":7.625272331154684,"y":62.36559139784946,"width":8.714596949891067,"height":17.204301075268816,"action":{"library":"H5P.Image 1.1","params":{"decorative":false,"contentName":"Image","expandImage":"Expand Image","minimizeImage":"Minimize Image","file":{"path":"images\/file-664dbc05e8943.png","mime":"image\/png","copyright":{"license":"U"},"width":128,"height":128}},"metadata":{"contentType":"Image","license":"U","title":"Untitled Image"},"subContentId":"0f7e3299-37ca-41a2-9d99-397b30a44abe"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":18.51851851851852,"y":49.46236559139785,"width":72.98474945533769,"height":34.40860215053763,"action":{"library":"H5P.Shape 1.0","params":{"shape":{"fillColor":"rgb(255, 235, 211)","borderWidth":"0","borderStyle":"solid","borderColor":"#000","borderRadius":"0"},"type":"rectangle","line":{"borderColor":"#000000","borderWidth":"1","borderStyle":"solid"}},"metadata":{"contentType":"Shapes","license":"U"},"subContentId":"1b7069b1-7aa2-42a0-a0f2-84cb33aa92de"},"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false},{"x":19.607843137254903,"y":51.61290322580645,"width":70.80610021786492,"height":32.25806451612903,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

For example, if there were 1,000 notified persons with TB<\/span><\/span><\/span> during a year, and 800 of them underwent UDST testing, the proportion of notified persons with TB<\/span><\/span><\/span> with UDST tested would be:<\/p>\n\n

(800\/1,000) x 100 = 80%<\/p>\n\n

So in this example, 80% of all notified persons with TB<\/span><\/span><\/span> underwent UDST testing.<\/p>\n"},"metadata":{"contentType":"Text","license":"U","title":"Untitled Text"},"subContentId":"474d0b3a-78c5-4dfe-b60f-02ff977c0b08"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":5.445108932461873,"y":4.295096774193548,"width":89.32461873638344,"height":36.55913978494623,"action":{"library":"H5P.Table 1.1","params":{"text":"

\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

Indicator <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t

Formula <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t

<\/td>\n\t\t<\/tr>\n\t\t

Proportion of persons with MDR TB initiated on treatment among diagnosed<\/strong><\/span><\/td>\n\t\t\t

Numerator:<\/span><\/span><\/span><\/td>\n\t\t\t

Number of notified persons with RR\/ MDR TB initiated on DRTB regimen<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t\t

Denominator:<\/span><\/span><\/span> <\/td>\n\t\t\t

Total persons with RR\/ MDR TB<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t\t

Multiplier:<\/span><\/span><\/span><\/td>\n\t\t\t

100<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"e14b11c8-aead-4651-b5e7-a13662944ee0","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":6.5359477124183005,"y":60.21505376344086,"width":8.714596949891067,"height":17.204301075268816,"action":{"library":"H5P.Image 1.1","params":{"decorative":false,"contentName":"Image","expandImage":"Expand Image","minimizeImage":"Minimize Image","file":{"path":"images\/file-664dbc05e8943.png","mime":"image\/png","copyright":{"license":"U"},"width":128,"height":128}},"metadata":{"contentType":"Image","license":"U","title":"Untitled Image"},"subContentId":"9c8fa739-ec2c-4487-ae12-ffac45d391ed"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":17.429193899782135,"y":47.25806451612903,"width":72.98474945533769,"height":38.70967741935483,"action":{"library":"H5P.Shape 1.0","params":{"shape":{"fillColor":"rgb(255, 235, 211)","borderWidth":"0","borderStyle":"solid","borderColor":"#000","borderRadius":"0"},"type":"rectangle","line":{"borderColor":"#000000","borderWidth":"1","borderStyle":"solid"}},"metadata":{"contentType":"Shapes","license":"U"},"subContentId":"87d1a88d-a73c-4149-a34c-8121747cfadb"},"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false},{"x":18.51851851851852,"y":49.37268817204301,"width":70.80610021786492,"height":36.55913978494623,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

For example, if there were 500 RR\/MDR TB notified patients during a year, and 400 of them were initiated on a DRTB treatment regimen, the proportion of MDR TB cases initiated on treatment among diagnosed would be:<\/p>\n\n

(400\/500) x 100 = 80%<\/p>\n\n

So in this example, 80% of all RR\/MDR TB notified patients were initiated on a DRTB treatment regimen.<\/p>\n"},"metadata":{"contentType":"Text","license":"U","title":"Untitled Text"},"subContentId":"3fa79301-32ba-4247-a31d-c547abe30a1e"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":5.445108932461873,"y":6.433698924731182,"width":89.32461873638344,"height":36.55913978494623,"action":{"library":"H5P.Table 1.1","params":{"text":"

\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

Indicator <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t

Formula <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t

<\/td>\n\t\t<\/tr>\n\t\t

Proportion of persons with Rif resistance subjected to baseline SL-LPA<\/span><\/strong><\/td>\n\t\t\t

Numerator:<\/span><\/span><\/span><\/td>\n\t\t\t

Number of persons with Rif resistance (RR\/MDR TB) subjected to baseline SL-LPA<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t\t

Denominator:<\/span><\/span><\/span> <\/td>\n\t\t\t

Total number of persons with Rif resistance (RR\/MDR TB) diagnosed<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t\t

Multiplier:<\/span><\/span><\/span><\/td>\n\t\t\t

100<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"25eeb58d-45bf-43d2-ac82-44ce11c05ab5","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":6.5359477124183005,"y":62.36559139784946,"width":8.714596949891067,"height":17.204301075268816,"action":{"library":"H5P.Image 1.1","params":{"decorative":false,"contentName":"Image","expandImage":"Expand Image","minimizeImage":"Minimize Image","file":{"path":"images\/file-664dbc05e8943.png","mime":"image\/png","copyright":{"license":"U"},"width":128,"height":128}},"metadata":{"contentType":"Image","license":"U","title":"Untitled Image"},"subContentId":"856b8a3d-3a41-473f-9fe6-3c4a0297aaa1"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":16.33986928104575,"y":49.46236559139785,"width":72.98474945533769,"height":38.70967741935483,"action":{"library":"H5P.Shape 1.0","params":{"shape":{"fillColor":"rgb(255, 235, 211)","borderWidth":"0","borderStyle":"solid","borderColor":"#000","borderRadius":"0"},"type":"rectangle","line":{"borderColor":"#000000","borderWidth":"1","borderStyle":"solid"}},"metadata":{"contentType":"Shapes","license":"U"},"subContentId":"2cde4de6-e9c8-4e03-864d-88d7c2c4c16d"},"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false},{"x":17.429193899782135,"y":51.61290322580645,"width":72.98474945533769,"height":39.956803455723545,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

For example, if there were 300 perons with Rif resistance (RR\/MDR TB) diagnosed during a year, and 240 of them underwent baseline SL-LPA testing, the proportion of persons with Rif resistance subjected to baseline SL-LPA would be:<\/p>\n\n

(240\/300) x 100 = 80%<\/p>\n\n

So in this example, 80% of all persons with Rif resistance (RR\/MDR TB) diagnosed underwent baseline SL-LPA testing.<\/p>\n"},"metadata":{"contentType":"Text","license":"U","title":"Untitled Text"},"subContentId":"225d6ca6-8d12-483a-99fc-39010fff8640"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":5.446623093681917,"y":6.451612903225806,"width":88.23529411764706,"height":40,"action":{"library":"H5P.Table 1.1","params":{"text":"

\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

Indicator <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t

Formula <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t

<\/td>\n\t\t<\/tr>\n\t\t

Proportion of individuals with results available among subjected to Base line SL-LPA<\/span><\/strong><\/td>\n\t\t\t

Numerator:<\/span><\/span><\/span><\/td>\n\t\t\t

Number of persons with RR\/ MDR TB with baseline SL-LPA results reported<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t\t

Denominator:<\/span><\/span><\/span> <\/td>\n\t\t\t

Number of persons with RR\/ MDR TB subjected to base line SL-LPA<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t\t

Multiplier:<\/span><\/span><\/span><\/td>\n\t\t\t

100<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"23a95af1-ed3f-435f-9058-2242dc39e772","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":6.5359477124183005,"y":60.21505376344086,"width":8.714596949891067,"height":17.204301075268816,"action":{"library":"H5P.Image 1.1","params":{"decorative":false,"contentName":"Image","expandImage":"Expand Image","minimizeImage":"Minimize Image","file":{"path":"images\/file-664dbc05e8943.png","mime":"image\/png","copyright":{"license":"U"},"width":128,"height":128}},"metadata":{"contentType":"Image","license":"U","title":"Untitled Image"},"subContentId":"a632d31d-470c-4c95-abf3-237a0a84b388"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":16.33986928104575,"y":49.46236559139785,"width":72.98474945533769,"height":38.70967741935483,"action":{"library":"H5P.Shape 1.0","params":{"shape":{"fillColor":"rgb(255, 235, 211)","borderWidth":"0","borderStyle":"solid","borderColor":"#000","borderRadius":"0"},"type":"rectangle","line":{"borderColor":"#000000","borderWidth":"1","borderStyle":"solid"}},"metadata":{"contentType":"Shapes","license":"U"},"subContentId":"00337a0f-4a2a-4954-bdb4-fcce4c325ddb"},"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false},{"x":17.429193899782135,"y":51.61290322580645,"width":74.07407407407408,"height":39.956803455723545,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

During a year, and results were reported for 180 of them, the proportion of patients with results available among those subjected to baseline SL-LPA would be:<\/p>\n\n

(180\/200) x 100 = 90%<\/p>\n\n

So in this example, 90% of all RR\/MDR TB patients who underwent baseline SL-LPA testing had their results reported.<\/p>\n"},"metadata":{"contentType":"Text","license":"U","title":"Untitled Text"},"subContentId":"70919ddc-ea4d-4585-9ef1-7e9bd7c7d578"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":4.357298474945534,"y":6.439655913978496,"width":90.41394335511983,"height":45.16129032258064,"action":{"library":"H5P.Table 1.1","params":{"text":"

\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

Indicator <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t

Formula <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t

<\/td>\n\t\t<\/tr>\n\t\t

Proportion of perosns with RR\/MDR TB with additional resistance to SLI or FQ or both SLI & FQ diagnosed among persons with RR\/ MDR TB with BL-SL LPA results reported<\/span><\/strong><\/td>\n\t\t\t

Numerator:<\/span><\/span><\/span><\/td>\n\t\t\t

Number of persons with RR\/ MDR TB with additional resistance diagnosed<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t\t

Denominator:<\/span><\/span><\/span> <\/td>\n\t\t\t

Number of persons with RR\/ MDR TB with base line SL-LPA results reported<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t\t

Multiplier:<\/span><\/span><\/span><\/td>\n\t\t\t

100<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"0d5e413b-2b31-4007-8d3a-3120e3966775","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":6.5359477124183005,"y":66.66666666666666,"width":8.714596949891067,"height":17.204301075268816,"action":{"library":"H5P.Image 1.1","params":{"decorative":false,"contentName":"Image","expandImage":"Expand Image","minimizeImage":"Minimize Image","file":{"path":"images\/file-664dbc05e8943.png","mime":"image\/png","copyright":{"license":"U"},"width":128,"height":128}},"metadata":{"contentType":"Image","license":"U","title":"Untitled Image"},"subContentId":"508902fa-fd71-4138-b4a2-cefa48388729"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":16.33986928104575,"y":49.402580645161294,"width":72.98474945533769,"height":45.16129032258064,"action":{"library":"H5P.Shape 1.0","params":{"shape":{"fillColor":"rgb(255, 235, 211)","borderWidth":"0","borderStyle":"solid","borderColor":"#000","borderRadius":"0"},"type":"rectangle","line":{"borderColor":"#000000","borderWidth":"1","borderStyle":"solid"}},"metadata":{"contentType":"Shapes","license":"U"},"subContentId":"43d52841-1a18-4de0-a4cc-a999bc04d56e"},"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false},{"x":17.429193899782135,"y":51.61290322580645,"width":70.80610021786492,"height":40,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

For example, if there were 150 persons with RR\/MDR TB with baseline SL-LPA results reported during a year, and 30 of them were diagnosed with additional resistance to SLI or FQ or both SLI & FQ, the proportion of persons with RR\/MDR TB with additional resistance would be:<\/p>\n\n

(30\/150) x 100 = 20%<\/p>\n\n

So in this example, 20% of all persons with RR\/MDR TB with baseline SL-LPA results reported were diagnosed with additional resistance to SLI or FQ or both SLI & FQ.<\/p>\n"},"metadata":{"contentType":"Text","license":"U","title":"Untitled Text"},"subContentId":"7420e8df-6501-4286-a123-17e018aba049"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":5.445108932461873,"y":6.439655913978496,"width":89.32461873638344,"height":40,"action":{"library":"H5P.Table 1.1","params":{"text":"

\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

Indicator <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t

Formula <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t

<\/td>\n\t\t<\/tr>\n\t\t

Proportion of persons with Rifampicin sensitive TB subjected to FL-LPA<\/span><\/strong><\/td>\n\t\t\t

Numerator:<\/span><\/span><\/span><\/td>\n\t\t\t

Number of persons with Rif sensitive TB subjected to baseline FL-LPA<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t\t

Denominator:<\/span><\/span><\/span> <\/td>\n\t\t\t

Total number of perons with Rif sensitive TB diagnosed<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t\t

Multiplier:<\/span><\/span><\/span><\/td>\n\t\t\t

100<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"ee85189c-2960-485c-a080-53aaac58a7a9","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":6.5359477124183005,"y":64.51612903225806,"width":8.714596949891067,"height":17.204301075268816,"action":{"library":"H5P.Image 1.1","params":{"decorative":false,"contentName":"Image","expandImage":"Expand Image","minimizeImage":"Minimize Image","file":{"path":"images\/file-664dbc05e8943.png","mime":"image\/png","copyright":{"license":"U"},"width":128,"height":128}},"metadata":{"contentType":"Image","license":"U","title":"Untitled Image"},"subContentId":"cd8b914e-ee6b-4caf-8907-1d523b612d43"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":16.33986928104575,"y":49.402580645161294,"width":72.98474945533769,"height":45.16129032258064,"action":{"library":"H5P.Shape 1.0","params":{"shape":{"fillColor":"rgb(255, 235, 211)","borderWidth":"0","borderStyle":"solid","borderColor":"#000","borderRadius":"0"},"type":"rectangle","line":{"borderColor":"#000000","borderWidth":"1","borderStyle":"solid"}},"metadata":{"contentType":"Shapes","license":"U"},"subContentId":"93451588-add0-48d1-8d65-8a8fd3fbcc71"},"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false},{"x":17.429193899782135,"y":53.76344086021505,"width":69.71677559912854,"height":40,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

For example, if there were 500 Rifampicin-sensitive TB patients diagnosed during a year, and 200 of them underwent baseline FL-LPA testing, the proportion of Rifampicin-sensitive TB patients subjected to FL-LPA would be:<\/p>\n\n

(200\/500) x 100 = 40%<\/p>\n\n

So in this example, 40% of all Rifampicin-sensitive TB patients diagnosed during the year underwent baseline FL-LPA testing.<\/p>\n"},"metadata":{"contentType":"Text","license":"U","title":"Untitled Text"},"subContentId":"e34d78d8-b38d-4f08-a4b7-a9d1a839632c"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":5.445108932461873,"y":4.295096774193548,"width":88.23529411764706,"height":40,"action":{"library":"H5P.Table 1.1","params":{"text":"

\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

Indicator <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t

Formula <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t

<\/td>\n\t\t<\/tr>\n\t\t

Proportion of persons with Rifampicin sensitive TB with H-mono \/ poly resistance report available among tested for FL-LPs<\/span><\/strong><\/td>\n\t\t\t

Numerator:<\/span><\/span><\/span><\/td>\n\t\t\t

Number of persons with Rifampicin sensitive TB with H-mono \/ poly resistance reports available<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t\t

Denominator:<\/span><\/span><\/span> <\/td>\n\t\t\t

Number of persons with Rifampicin sensitive TB subjected to FL-LPA<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t\t

Multiplier:<\/span><\/span><\/span><\/td>\n\t\t\t

100<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"5c258caa-ba93-4976-8c3e-a4aa17442a7d","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":6.5359477124183005,"y":64.51612903225806,"width":8.714596949891067,"height":17.204301075268816,"action":{"library":"H5P.Image 1.1","params":{"decorative":false,"contentName":"Image","expandImage":"Expand Image","minimizeImage":"Minimize Image","file":{"path":"images\/file-664dbc05e8943.png","mime":"image\/png","copyright":{"license":"U"},"width":128,"height":128}},"metadata":{"contentType":"Image","license":"U","title":"Untitled Image"},"subContentId":"b3743a4f-a9f9-4744-b922-fe9dde359783"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":16.33986928104575,"y":47.284946236559136,"width":79.520697167756,"height":47.31182795698924,"action":{"library":"H5P.Shape 1.0","params":{"shape":{"fillColor":"rgb(255, 235, 211)","borderWidth":"0","borderStyle":"solid","borderColor":"#000","borderRadius":"0"},"type":"rectangle","line":{"borderColor":"#000000","borderWidth":"1","borderStyle":"solid"}},"metadata":{"contentType":"Shapes","license":"U"},"subContentId":"7a1cd27b-ce4c-4576-8e5c-8acb80d43419"},"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false},{"x":17.429193899782135,"y":49.46236559139785,"width":77.34204793028323,"height":45.376344086021504,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

For example, if there were 200 persons with Rifampicin sensitive TB<\/span><\/span><\/span> who underwent FL-LPA testing during a year, and 50 of them were diagnosed with H-mono\/poly resistance and had the resistance report available, the proportion of persons with Rifampicin sensitive TB <\/span><\/span><\/span>with H-mono\/poly resistance report available among those tested for FL-LPA would be:<\/p>\n\n

(50\/200) x 100 = 25%<\/p>\n\n

So in this example, 25% of all persons with Rifampicin sensitive TB<\/span><\/span><\/span> who underwent FL-LPA testing during the year and were diagnosed with H-mono\/poly resistance had the resistance report available.<\/p>\n"},"metadata":{"contentType":"Text","license":"U","title":"Untitled Text"},"subContentId":"1658505d-43c9-4a62-a9fe-1fdf1ea4e44c"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":5.445108932461873,"y":4.295096774193548,"width":89.32461873638344,"height":40,"action":{"library":"H5P.Table 1.1","params":{"text":"

\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

Indicator <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t	Formula <\/span><\/span><\/span><\/strong><\/td>\n\t\t\t	<\/td>\n\t\t<\/tr>\n\t\t
Proportion of persons with H-mono \/ poly resistant TB diagnosed amongst those subjected to FLLPA<\/span><\/strong><\/td>\n\t\t\t	Numerator:<\/span><\/span><\/span><\/td>\n\t\t\t	Number of persons with Rifampicin sensitive TB with H-mono \/ poly resistance diagnosed<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t\t
Denominator:<\/span><\/span><\/span> <\/td>\n\t\t\t	Number of persons with Rifampicin sensitive TB subjected to FL-LPA with reports available<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t\t
Multiplier:<\/span><\/span><\/span><\/td>\n\t\t\t	100<\/span><\/span><\/span><\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"931656b4-a3f0-4368-a107-1e06cb386f3f","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":6.5359477124183005,"y":62.36559139784946,"width":8.714596949891067,"height":17.204301075268816,"action":{"library":"H5P.Image 1.1","params":{"decorative":false,"contentName":"Image","expandImage":"Expand Image","minimizeImage":"Minimize Image","file":{"path":"images\/file-664dbc05e8943.png","mime":"image\/png","copyright":{"license":"U"},"width":128,"height":128}},"metadata":{"contentType":"Image","license":"U","title":"Untitled Image"},"subContentId":"5b160fa4-b8b6-4ced-a0a4-d87478efd309"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":16.33986928104575,"y":47.31182795698924,"width":79.520697167756,"height":47.31182795698924,"action":{"library":"H5P.Shape 1.0","params":{"shape":{"fillColor":"rgb(255, 235, 211)","borderWidth":"0","borderStyle":"solid","borderColor":"#000","borderRadius":"0"},"type":"rectangle","line":{"borderColor":"#000000","borderWidth":"1","borderStyle":"solid"}},"metadata":{"contentType":"Shapes","license":"U"},"subContentId":"7bc80143-5859-4421-b566-71032af30116"},"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false},{"x":17.429193899782135,"y":49.46236559139785,"width":79.520697167756,"height":44.3010752688172,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":" For example, if there were 200 persons with Rifampicin sensitive TB <\/span><\/span><\/span>who underwent FL-LPA testing during a year, and 100 of them had the resistance report available, out of which 20 were diagnosed with H-mono\/poly resistance, the proportion of H-mono\/poly resistance TB cases diagnosed among those subjected to FLLPA would be:<\/p>\n\n (20\/100) x 100 = 20%<\/p>\n\n So in this example, 20% of all persons with Rifampicin sensitive TB<\/span><\/span><\/span> who underwent FL-LPA testing during the year and had the resistance report available were diagnosed with H-mono\/poly resistance.<\/p>\n"},"metadata":{"contentType":"Text","license":"U","title":"Untitled Text"},"subContentId":"657a109c-0781-4d6f-98b4-bfe8ddb082b9"},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}}],"keywordListEnabled":true,"globalBackgroundSelector":{},"keywordListAlwaysShow":false,"keywordListAutoHide":false,"keywordListOpacity":90},"override":{"activeSurface":false,"hideSummarySlide":false,"summarySlideSolutionButton":true,"summarySlideRetryButton":true,"enablePrintButton":false,"social":{"showFacebookShare":false,"facebookShare":{"url":"@currentpageurl","quote":"I scored @score out of @maxScore on a task at @currentpageurl."},"showTwitterShare":false,"twitterShare":{"statement":"I scored @score out of @maxScore on a task at @currentpageurl.","url":"@currentpageurl","hashtags":"h5p, course"},"showGoogleShare":false,"googleShareUrl":"@currentpageurl"}},"l10n":{"slide":"Slide","score":"Score","yourScore":"Your Score","maxScore":"Max Score","total":"Total","totalScore":"Total Score","showSolutions":"Show solutions","retry":"Retry","exportAnswers":"Export text","hideKeywords":"Hide sidebar navigation menu","showKeywords":"Show sidebar navigation menu","fullscreen":"Fullscreen","exitFullscreen":"Exit fullscreen","prevSlide":"Previous slide","nextSlide":"Next slide","currentSlide":"Current slide","lastSlide":"Last slide","solutionModeTitle":"Exit solution mode","solutionModeText":"Solution Mode","summaryMultipleTaskText":"Multiple tasks","scoreMessage":"You achieved:","shareFacebook":"Share on Facebook","shareTwitter":"Share on Twitter","shareGoogle":"Share on Google+","summary":"Summary","solutionsButtonTitle":"Show comments","printTitle":"Print","printIngress":"How would you like to print this presentation?","printAllSlides":"Print all slides","printCurrentSlide":"Print current slide","noTitle":"No title","accessibilitySlideNavigationExplanation":"Use left and right arrow to change slide in that direction whenever canvas is selected.","accessibilityCanvasLabel":"Presentation canvas. Use left and right arrow to move between slides.","accessibilityProgressBarLabel":"Choose slide to display","containsNotCompleted":"@slideName contains not completed interaction","containsCompleted":"@slideName contains completed interaction","slideCount":"Slide @index of @total","containsOnlyCorrect":"@slideName only has correct answers","containsIncorrectAnswers":"@slideName has incorrect answers","shareResult":"Share Result","accessibilityTotalScore":"You got @score of @maxScore points in total","accessibilityEnteredFullscreen":"Entered fullscreen","accessibilityExitedFullscreen":"Exited fullscreen","confirmDialogHeader":"Submit your answers","confirmDialogText":"This will submit your results, do you want to continue?","confirmDialogConfirmText":"Submit and see results","slideshowNavigationLabel":"Slideshow navigation"}}

Search

Monitoring indicators related to UDST

Content Status

Type

Linked Node

Monitoring indicators related to UDST

Page Tags

Content Creator

Reviewer

Target Audience

Comments